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Hypertension is a heritable and major contributor to the global burden of disease. The sum of rare and common genetic
variants robustly identified so far explain only 1%–2% of the population variation in BP and hypertension. This suggests the
existence of more undiscovered common variants. We conducted a genome-wide association study in 1,621 hypertensive
cases and 1,699 controls and follow-up validation analyses in 19,845 cases and 16,541 controls using an extreme case-
control design. We identified a locus on chromosome 16 in the 59 region of Uromodulin (UMOD; rs13333226, combined P
value of 3.6610
211). The minor G allele is associated with a lower risk of hypertension (OR [95%CI]: 0.87 [0.84–0.91]),
reduced urinary uromodulin excretion, better renal function; and each copy of the G allele is associated with a 7.7%
reduction in risk of CVD events after adjusting for age, sex, BMI, and smoking status (H.R.=0.923, 95% CI 0.860–0.991;
p=0.027). In a subset of 13,446 individuals with estimated glomerular filtration rate (eGFR) measurements, we show that
rs13333226 is independently associated with hypertension (unadjusted for eGFR: 0.89 [0.83–0.96], p=0.004; after eGFR
adjustment: 0.89 [0.83–0.96], p=0.003). In clinical functional studies, we also consistently show the minor G allele is
associated with lower urinary uromodulin excretion. The exclusive expression of uromodulin in the thick portion of the
ascending limb of Henle suggests a putative role of this variant in hypertension through an effect on sodium homeostasis.
The newly discovered UMOD locus for hypertension has the potential to give new insights into the role of uromodulin in BP
regulation and to identify novel drugable targets for reducing cardiovascular risk.
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Introduction
Hypertension is a major cardiovascular risk factor with a global
prevalence of 26.4% in 2000, projected to increase to 29.2% by
2025, and is the leading contributor to global mortality[1,2].
While epidemiologically BP is a trait continuously associated with
an increased risk of cardiovascular mortality and morbidity,
clinical risk assessment is necessarily based on a predefined
threshold at which the quantitative BP phenotype is converted into
a binary trait (hypertension) [3–6]. The main justification for large
scale efforts to determine the genetic underpinnings of BP
regulation is to identify new pharmacological targets for BP
reduction while advancing our understanding of blood pressure
regulation. This in turn could lead to novel prevention strategies to
reduce the growing public health burden of hypertension-related
cardiovascular disease [2,7]. Systemic blood pressure (BP) is
determined primarily by cardiac output and total peripheral
resistance, which are controlled by a complex network of
interacting pathways involving renal, neural, endocrine, vascular
and environmental factors. So far, the search for common variants
affecting BP has identified thirteen loci from two large meta-
analyses consortia, with each association explaining only a very
small proportion of the total variation in systolic or diastolic blood
pressure (SBP or DBP; ,0.05–0.10%, approximately 1 mmHg
per allele SBP or 0.5 mmHg per allele DBP)[8,9]. The sum of rare
and common genetic variants robustly identified so far through
linkage and genome wide association studies explain only 1–2% of
the population variation in BP and hypertension. These data
suggest the existence of more undiscovered blood pressure related
common variants. Cross-sectional studies of the general population
have required extremely large sample sizes to detect such small
effect sizes [10]. In this paper we explored an alternative strategy to
increasepower,usingcasesandcontrolsdrawnfromtheextremesof
the BP distribution, and detected a novel locus associated with
hypertension. We then validated this association using large-scale
population and case-control studies, where similar extreme criteria
for selection of cases and controls have been used. As the locus was
related to uromodulin, a protein exclusively expressed intrarenally,
we tested for dependency of the association on renal function
(eGFR) and urinary excretion of uromodulin. Finally, we tested
associations with cardiovascular outcomes.
Results
Genome-wide association, replication, and meta-analysis
The demographic characteristics of the discovery and validation
cohorts are presented in Table 1 and Table S1 respectively. The
results of the GWASin the discovery sample are presented in Figure 1.
The observed versus expected p-value distributions (quantile-quantile
plots) are shown in Figure 2. The top hit was rs13333226 with the
minor G allele associated with a lower risk of hypertension (OR
[95%CI]: 0.6 [0.5–0.73]; p=1.14610
27;F i g u r e3 )a n dw es e l e c t e d
this for validation in two stages (Figure S1, Table 2 and Table 3). In
the first stage we genotyped rs13333226 in the MONICA/PAMELA
population samples (in which we also genotyped an additional top 88
SNPs – Table S2) and in the larger MDC and MPP validation case-
control populations.For the stage 1 validation,we had 9,827 cases and
8,694 controls and the combined analysis showed the minor G allele
GWAS of Blood Pressure Extremes
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p=3.6 610
26) after adjustment for age, age
2 and BMI. Combined
analysis of the 89 SNPs genotyped in the MONICA/PAMELA with
the discovery cohort showed rs13333226 (p=3.86610
27)a n d
rs4293393 (p=3.30610
27,r
2=0.996) were the top SNPs. In stage
2 analysis which included 10,018 cases and 7,847 controls, the results
were similar with the G allele associated with a lower risk of
hypertension (0.86 [0.81–0.92]; p=1.0610
25). Combining stage 1
and stage 2 cohorts increased the strength of association (0.86 [0.83–
0.90]; p=1.61610
210). There was no evidence of heterogeneity
across the stage 1 or stage 2 samples or the combined stage 1 and 2
samples as tested by the Q statistic (p.0.05). Merging stages 1 and 2
with the discovery samples yielded the strongest association signal for
rs13333226 (0.85 [0.81–0.89]; p=1.5610
213)w i t hs o m ee v i d e n c eo f
heterogeneity (Q statistic p value=0.04) introduced by the discovery
cohort (Table 2, Figure 4A and 4B, Figure S2). This is probably due to
the fact that the discovery cohort was ascertained using more extreme
criteria than the replication cohorts. In the 13,446 individuals with
eGFR measurements available, the strength of association of
rs13333226 with hypertension was identical after correcting for
eGFR and the effect sizes remained unchanged (unadjusted for eGFR:
OR [95%CI] =0.90[0.83;0.96], p=0.004; after eGFR adjustment:
OR [95%CI]=0.89[0.83;0.96], p=0.003) and there was no evidence
of heterogeneity across the studysamples (Table 3,Figure 4Cand 4D).
Association with SBP and DBP
We examined association of rs13333226 with continuous blood
pressure measurementsin the entire Global BPgen,MPP and MDC
cohorts (n=79,133). Each copy of the G allele of rs13333226 is
associated with 0.49 mmHg lower SBP (p=2.6610
25)a n d
0.30 mmHg lower DBP ( p=1.5610
25). The direction of
continuous trait effect is consistent with the odds of hypertension.
Clinical functional studies
The SNP rs13333226 is in close proximity to the uromodulin
transcription start site at 21617 base pairs (Figure 3). We studied
the association between rs13333226 genotypes and different
phenotypes including urinary uromodulin, in 256 hypertensive
individuals fromthe BRIGHTcohortand110participantsfrom the
population-based HERCULES study. Univariate analyses showed
that the G allele was associated with lower excretion of uromodulin
in both the BRIGHT and HERCULES studies (Table 4 and
Table 5). Each copy of the G allele was associated with 0.2 mg/
mmol lower urinary uromodulin corrected for urine creatinine in
BRIGHT study (p=0.007). Each copy of the G allele was also
associated with 4.6 ml/min/1.73 m
2 higher eGFR (p=0.005) in
the BRIGHT cohort. In HERCULES, however, a higher
creatinine clearance in GG individuals did not attain statistical
significance. In both studies the association of rs13333226 with
urinary uromodulin levels persisted on multiple regression analysis
adjusting for sex, urine sodium and eGFR (p,0.001).
In BRIGHT, GG carriers were found to have a significantly
lower fractional excretion of sodium (p=0.032). In the smaller
HERCULES sample this also occurred, though short of statistical
significance. However, in HERCULES urinary uromodulin was
positively associated with urinary sodium excretion (p=0.025) and
fractional excretion of endogenous lithium (r
2=0.19, p=0.045).
Overall, BRIGHT and HERCULES data suggest that low urinary
uromodulin is associated with higher sodium reabsorption, and that
this occurs at the proximal tubular level.
In the small GRECO cohort, urinary uromodulin concentration
(p=0.004) and 24 hour uromodulin excretion (p=0.002; Wilcox-
on9s signed ranks test) were found to be significantly increased after
a high sodium intake (Table 6). The G allele was associated with
lower uromodulin excretion only on low sodium diet (p=0.002).
Cardiovascular outcomes and rs13333226
Finally, we evaluated the clinical significance of our findings by
testing whether the low BP associated allele may protect against
development of cardiovascular events during long-term follow-up
at the population level. Among 26,654 subjects from the entire
population based MDC study [11] who were free from prior
cardiovascular events at baseline, 2,750 individuals developed
cardiovascular events (CVD) during 12 years of follow-up. We
found each copy of the G allele to be associated with a 7.7%
reduction in risk of CVD events after adjusting for age, sex, BMI
and smoking status (H.R. =0.923, 95% CI 0.860–0.991;
p=0.027). When SBP (H.R. =0.936, 95% CI 0.872–1.005;
p=0.067) or SBP and DBP (H.R. =0.937, 95% CI 0.873–1.005;
p=0.069) were added to the Cox regression model, the
directionality and risk remained almost identical.
Discussion
We have identified and validated a SNP upstream of the
uromodulin (UMOD) gene whose minor allele is associated with a
Author Summary
Hypertension is the leading contributor to global mortality
with a global prevalence of 26.4% in 2000, projected to
increase to 29.2% by 2025. While 50%–60% of population
variation in blood pressure can be attributable to additive
genetic factors, all the genetic variants robustly identified
so far explain only 1%–2% of the population variance
indicating the presence of additional undiscovered risk
variants. Using an extreme case-control strategy, we have
discovered a SNP in the promoter region of the
uromodulin gene (UMOD) to be associated with hyper-
tension (minor allele protective against hypertension). We
then validated this association using large-scale popula-
tion and case-control studies, where similar extreme
criteria for selection of cases and controls have been used
(21,466 cases and 18,240 controls). As the locus was
related to uromodulin, a protein exclusively expressed in
the kidneys, we show that the association is independent
of renal dysfunction. We also show preliminary evidence
that the SNP allele which is protective against hyperten-
sion is also protective against cardiovascular events in
26,654 Swedish subjects followed-up for 12 years. The
newly discovered UMOD locus for hypertension has the
potential to give unique insights into the role of
uromodulin in BP regulation and to identify novel
drugable targets.
Table 1. Demographic characteristics of the discovery case
control population.
Controls
(n=1699)
Cases
(n=1621) p
Age at enrolment, years 57.4 (5.9) 55.4 (7.1) ,0.001
BMI, kg/m
2 24.2 (3.5) 27.1 (7.8) ,0.001
SBP, mmHg 115.8 (6.8) 175.8 (22.5) ,0.001
DBP, mmHg 73.7 (5.7) 104.7 (11.8) ,0.001
doi:10.1371/journal.pgen.1001177.t001
GWAS of Blood Pressure Extremes
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close proximity to the uromodulin transcription start site at 21617
base pairs. There is only one previous candidate gene study of
UMOD and hypertension. This study tested rs6497476, located in
the 59 region of the UMOD gene (2744 bp from UMOD
transcriptional start point) and showed the minor allele with a
lower risk of hypertension in a Japanese population, but it did not
reach statistical significance [12]. This SNP is correlated with
rs13333226 in the Japanese HapMap population (r
2=0.91) and
shows the same directionality of effect. A recent genome scan for
chronic kidney disease (CKD) [13] has found the minor T allele at
rs12917707, 23653 bp upstream from the UMOD transcription
start site to be associated with a 20% reduction in risk of CKD.
This association was consistent after adjusting for major CKD risk
factors including SBP and hypertension. This SNP -rs12917707 is
perfectly correlated (r
2=1 in HapMap CEU) with rs13333226.
Our data show the minor allele of rs13333226 is associated with
increased eGFR (beta=3.6, p=0.012), but adjustment for eGFR
in our meta-analyses did not alter its association with lower risk for
hypertension. This suggests that the UMOD locus is indepen-
dently associated with hypertension. We also show an association
of rs13333226 with long term cardiovascular outcomes with a
relatively small attenuation of the relationship after SBP/DBP
adjustment. This suggests UMOD may have an influence on
cardiovascular disease at least partly independent of BP. However,
our conditional analyses are limited by the fact that single point
measures of BP and eGFR may not truly represent the lifetime
effect of the genetic variant on these traits. Therefore, we cannot
exclude that rs13333226 may exert its effects on hypertension and
cardiovascular disease, at least partly through its effects on renal
function and blood pressure, respectively.
The UMOD gene encodes the Tamm Horsfall protein (THP)/
uromodulin, a glycosylphosphatidylinositol (GPI) anchored glyco-
protein. It is the most abundant tubular protein in the urine, which
is expressed primarily in the thick ascending limb of the loop of
Henle (TAL) with negligible expression elsewhere [14,15]. We
show in the BRIGHT, HERCULES and GRECO (low sodium
diet) that the minor allele of rs13333226 (associated with a lower
risk of hypertension) is consistently associated with lower urinary
uromodulin excretion. This effect was lost when GRECO subjects
were given a high sodium diet. We also show in BRIGHT and
HERCULES that the G allele and lower urinary uromodulin are
associated with lower fractional excretion of sodium and lower
fractional excretion of endogenous lithium, indicating increased
sodium reabsorption at the proximal tubular level. While the
association of lower blood pressure and increased sodium
reabsorption may appear counterintuitive, an increased sodium
reabsorption by the proximal tubule may simply be the
consequence of an increased sodium load because of increased
GFR, or a compensatory reaction to a primary decrease in distal
reabsorption. In absence of information on sodium intake in
individuals in BRIGHT and HERCULES, we cannot exclude that
the lower fractional sodium excretion in carriers of the G allele
simply reflects a low dietary sodium intake. The exclusive
expression of uromodulin in TAL, where physiologically crucial
mechanisms of sodium handling are located, suggests that
alterations of some of these mechanisms in G allele carriers may
underlie their lower risk of hypertension. However, functional
studies are needed to clarify the renal mechanisms by which the
UMOD gene may affect hypertension and renal sodium handling.
In the context of our findings it is of interest to note that UMOD
mutations (in exons 4 and 5) are implicated in monogenic
Figure 1. Manhattan plot of genomewide –log10(p-value) from association analysis of BP extremes in the discovery sample.
doi:10.1371/journal.pgen.1001177.g001
GWAS of Blood Pressure Extremes
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autosomal-dominant medullary cystic kidney disease [MCKD2]
and glomerulocystic kidney disease (GCKD) (MIM603860,
MIM162000, MIM609886) [16–18]. In previous small studies,
urinary uromodulin levels were found to be decreased in older
subjects and in subjects with renal impairment [19,20]. In renal
disease patients, uromodulin excretion was reduced in proportion
to the extent of renal damage, and was a marker of distal tubular
sodium reabsorption, but in these studies, the effects of BP on
uromodulin were inconsistent [21,22]. The TAL, where UMOD is
selectively expressed is also the site where mutations of tubular
transporters have resulted in rare Mendelian high or low BP
syndromes [23]. Furthermore, recent data from Lifton’s group
demonstrated that heterozygous mutations in SLC12A3 (encoding
the thiazide-sensitive Na-Cl cotransporter), SLC12A1 (encoding
the Na-K-Cl cotransporter NKCC2), and KCNJ1 (encoding the
K+ channel ROMK) discovered in the general population have
been associated with lower BP and a 60% reduction in the
development of hypertension [24].
Our strategy of using extremes of BP distribution has led to the
discovery of a gene variant that could not be discovered when a
less stringent case-control definition was used [10]. For example,
in stage 1 Global BPgen samples (n=34,433), the p values for
association of rs13333226 with SBP and DBP were 0.0077 and
0.0099 respectively indicating that rs13333226 would not have
been selected for validation as the p-value threshold for follow-up
genotyping in that study was p,10
25. Also, in Global BPgen study
when the top 8 SNPs that attained genome wide significance for
continuous BP were tested for association with hypertension, four
of the eight SNPs had 0.01,p#0.10 with odds of hypertension in
directions consistent with the continuous trait effect. As effect size
of the risk allele of rs13333226 is comparable to the effect sizes of
the previous robust association signals for blood pressure[8,9], we
think that using an extreme case-control strategy successfully
enabled the discovery of a locus that previous GWAS meta-
analysis failed to detect possibly due to the cost imposed by
multiple testing correction.
The main limitation of our study is that the functional studies
were performed on three different populations – hypertensive,
population-based and dietary sodium intervention samples. The
renal and blood pressure measurements were measured at single
time-points and are not entirely representative of genotype-
phenotype effects which occur over prolonged time periods. On
the other hand, definitions of the extreme hypertension and
extreme normotension in the discovery cohort are based on very
robust data. Subjects with extreme hypertension were chosen from
an intervention trial in which blood pressure was measured after a
wash-out period during which all antihypertensive therapy was
discontinued before randomization, whereas normotensive con-
trols were chosen from a population followed up for 10 years and
who remained free of cardiovascular disease and antihypertensive
treatment throughout this period. Therefore, we think that the
newly discovered UMOD locus for hypertension has the potential
to give unique insights into the mechanisms of high blood pressure,
and identify novel drugable targets.
Methods
Ethical considerations
All studies were approved by institutional ethics review
committees at the relevant organizations. All participants provided
informed written consent.
Figure 2. Quantile-Quantile plot of observed versus expected p-value distributions in the discovery sample.
doi:10.1371/journal.pgen.1001177.g002
GWAS of Blood Pressure Extremes
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To identify novel susceptibility loci for hypertension, we used an
extreme case-control design. Hypertensive cases had to have at
least two consecutive BP measurements of $160 mmHg systolic
and $100 mmHg diastolic, with the diagnosis made before age 63
years. We identified 2,000 cases in the Nordic Diltiazem study
(NORDIL) [25]. These hypertensive subjects represent approxi-
mately the top 2% of the BP distribution in the Swedish
population. Two thousand control subjects were drawn from the
Malmo ¨ Diet and Cancer study (MDC, n=27,000) [26] who had a
SBP# 120 mmHg and DBP# 80 mmHg. Controls had to be at
least 50 years of age and free from cardiovascular events (coronary
events and stroke) during 10 years of follow up [27] and not on any
antihypertensive medication. The controls derived from the MDC
population represented the lower 9.2% of the BP distribution and
with the selection for low cardiovascular risk, can be considered as
hyper-controls. In both NORDIL and MDC, BP was measured in
the recumbent position after 5–10 minutes rest using a manual
sphygmomanometer. Rigorously phenotyped samples minimize
case/control misclassification, and the potential advantage of an
extreme case/control design is greater power to detect variants
associated with BP and hypertension, for a given total sample size
and total genotyping cost.
Validation cohorts
For the validation we used phenotypic definitions (extreme
SBP/DBP thresholds) to closely match our discovery samples. The
BP measurements in all the cohorts were based on the average of
at least 2 measurements obtained when the subject was seated and
after rest for at least 5 minutes. The BP criteria were slightly
modified as most validation cohorts were general population
cohorts. Cases: Individuals less than 60 years of age with SBP
$140 mmHg or DBP $90 mmHg or current treatment with
antihypertensive or BP lowering medication commenced before
age 60 years. Controls: Individuals with SBP #120 mmHg and
DBP #80 mmHg, at least 50 years of age, and free from any BP
lowering medication. If age #50 years, then the criteria were
slightly modified to SBP #115 mmHg and DBP #80 mmHg and
free from BP lowering medications. The validation cohorts were
the MONItoring trends and determinants of CArdiovascular
diseases (MONICA)/Pressioni Arteriose Monitorate E Loro
Associazioni (PAMELA) studies (894 cases/746 controls) from
Northern Italy [6,28], 1956 cases/1057 controls from the 2002–
2006 follow-up exam of the Malmo ¨ Preventive Project (MPP) [29]
and 6977 cases/6891 controls from the Malmo ¨ Diet and Cancer
study [11] (MDC; non-overlapping with discovery samples), 509
cases/209 controls from The Netherlands Study of Depression
and Anxiety study (NESDA) [30] and ten cohorts from a
collaboration with the Global BPgen consortium [9]. Analyses
reported here are distinct from those previously published [9],
because they use phenotypic definitions to match our discovery
samples. The combined sample size of the discovery and
validation cohorts is 39,706 individuals (21,466 cases and 18,240
controls).
Estimated glomerular filtration rate (eGFR) was calculated
using the Modification of Diet in Renal Disease (MDRD) Study
equation [31].
Clinical functional studies
We studied functional associations of the top SNP in a
hypertensive cohort and a population cohort with extensive urine
phenotypes and one interventional study of low and high sodium
intake with extensive measurements of sodium balance.
The British Genetics of Hypertension (BRIGHT) study [32] is a
hypertension case-control study. Case inclusion criterion was a
diagnosis of hypertension (.150/100 mmHg) prior to 50 years of
age. Exclusion criteria included BMI.35, diabetes, secondary
hypertension or co-existing illness. 24-hour urine collection was
Figure 3. Association plot of the genomic region around rs13333226 showing both typed and imputed SNPs with location of genes
and recombination rate.
doi:10.1371/journal.pgen.1001177.g003
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Adjusted for age, age
2,
sex, BMI
Adjusted for age, age
2, sex,
BMI, eGFR
controls cases eGFR mean eGFR SD OR [95%-CI] p OR [95%-CI] p
PREVEND 2404 1606 80.36 14.39 0.9 [0.77;1.03] 0.113 0.89 [0.77;1.03] 0.135
CoLaus 1375 1298 83.28 16.35 0.93 [0.79;1.1] 0.375 0.93 [0.79;1.1] 0.377
SHIP 240 656 87.62 19.78 0.74 [0.5;1.11] 0.137 0.74 [0.5;1.1] 0.144
DGI 120 141 72.69 11.67 1.09 [0.69;1.72] 0.482 1.094 [0.78;1.68] 0.698
Fenland 508 262 98.92 52.96 0.8 [0.58;1.1] 0.158 0.80 [0.58;1.09] 0.174
MONICA/PAMELA 824 719 84.3 16.59 0.87 [0.72;1.05] 0.145 0.89 [0.74;1.09] 0.278
MPP 1956 1057 88.2 15.1 0.91 [0.78–1.05] 0.186 0.90 [0.78;1.05] 0.179
Combined Analysis 7427 5739 0.899 [0.83; 0.97] 0.0036 0.893 [0.83; 0.96] 0.003
P value of the meta-analysis Q test for heterogeneity=0.87.
doi:10.1371/journal.pgen.1001177.t003
Table 2. Results from the meta-analysis of rs13333226 and HTN in discovery sample and after validation.
Study origin cases controls maf Unadjusted Analysis Adjusted for age, age
2, sex BMI
Q (Unadj/
Adj)
OR [95%-CI] p OR [95%-CI] p
Swedish BP Extremes
(Discovery)
Swedish 1621 1699 0.17 0.65 [0.56–0.76] 1.10610
207 0.6 [0.5–0.73] 3.3610
207
Stage 1
MONICA/PAMELA Italian 894 746 0.19 0.91 [0.76–1.08] 0.282 0.87 [0.72–1.05] 0.145
MPP Swedish 1956 1057 0.18 0.91 [0.78–1.05] 0.193 0.91 [0.78–1.05] 0.186
MDC Swedish 6977 6891 0.18 0.86 [0.80–0.92] 0.001 0.86 [0.80–0.92] 3.0610
205
Stage 1 Analysis 9827 8694 0.183 0.87 [0.82–0.93] 6.7610
26 0.87 [0.82–0.92] 3.6610
26 0.73/0.81
Stage 1 + Discovery 21275 19087 0.18 0.84 [0.79–0.89] 4.4610
210 0.84 [0.79–0.89] 2.5610
29 0.01/0.01
Stage 2
BRIGHT/ASCOT British/Irish 3069 1787 0.18 0.94 [0.84–1.04] 0.229 0.9 [0.80–1.02] 0.103
PREVEND Dutch 2411 1613 0.18 0.9 [0.80–1.02] 0.091 0.89 [0.77–1.03] 0.113
CoLaus Swiss 1300 1375 0.19 0.97 [0.84–1.11] 0.634 0.93 [0.79–1.1] 0.375
KORA German 457 300 0.16 0.8 [0.61–1.06] 0.128 0.7 [0.51–0.97] 0.03
SHIP German 656 240 0.18 1.07 [0.81–1.41] 0.627 0.74 [0.50–1.1] 0.137
58BC British 514 529 0.19 0.82 [0.66–1.02] 0.077 0.77 [0.61–0.97] 0.026
TwinsUK British 245 845 0.19 0.88 [0.68–1.14] 0.332 0.84 [0.63–1.12] 0.236
MIGen European
Ancestry
316 278 0.21 0.68 [0.51–0.9] 0.004 0.61 [0.44–0.84] 0.002
DGI Swedish/
Finnish
277 161 0.23 1.11 [0.77–1.62] 0.572 1.15 [0.78–1.68] 0.483
Fenland British 264 510 0.19 0.91 [0.69–1.19] 0.478 0.8 [0.58–1.09] 0.158
NESDA Dutch 509 209 0.18 0.98 [0.73–1.31] 0.898 0.93 [0.63–1.35] 0.689
Stage 2 Analysis 10018 7847 0.189 0.91 [0.86–0.96] 0.0019 0.86 [0.81–0.92] 1.0610
25 0.5/0.3
Stage 2 + Discovery 11639 9546 0.188 0.88 [0.83–0.93] 1.2610
26 0.83 [0.78–0.88] 5.4610
29 0.01/0.02
Combined Analysis -
Stage 1 + Stage 2
19845 16541 0.188 0.89 [0.86–0.93] 7.36610
208 0.86 [0.83–0.90] 1.61610
210 0.52/0.51
Combined Analysis -
Discovery + Stage 1
+ Stage 2
21466 18240 0.187 0.87 [0.84– 0.91] 3.60610
211 0.85 [0.81– 0.89] 1.5610
213 0.02/0.04
Q(unadj/adj) =P value of the meta-analysis Q test for heterogeneity for the unadjusted and adjusted meta-analysis respectively.
doi:10.1371/journal.pgen.1001177.t002
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potassium, creatinine and microalbuminuria. We measured
urinary uromodulin in 256 hypertensive subjects.
Groningen Renal Hemodynamic Cohort Study Group
(GRECO): The GRECO protocol comprises integrated measure-
ment of renal hemodynamics and extracellular volume as applied
in an ongoing series of studies in healthy subjects [33,34]. For the
current analysis 64 healthy adult males were included (mean
age=23 years), who had been studied after two seven-day periods:
the first 7 days on a low sodium diet (LS, 50 mmol Na
+ per day,
balance verified by repeated 24 h urine), the second 7 days on a
high-sodium diet (HS, 200 mmol Na
+ per day).
Hypertension Evaluation by Remler and CalciUria LEvel Study
(HERCULES) is a substudy of the population-based CoLaus study
(www.colaus.ch) from Lausanne Switzerland [35,36]. A random
sample of 411 CoLaus participants, aged 38–78 years, underwent
ambulatory BP monitoring and 24 hour urine collection. The
phenotypes available include 24-hour urine collection with measure-
ment of creatinine clearance, endogenous lithium clearance, urinary
sodium, potassium and uric acid excretion and microalbuminuria.
We measured urinary uromodulin in 110 participants of this study.
Urinary uromodulin measurements
Urinary uromodulin was measured in duplicate in 24 hour
urine samples using a commercially available ELISA (MD
Biosciences, Zu ¨rich, Switzerland) as recommended by the
manufacturer. The range of assay is 9.375–150 ng/mL and
sensitivity ,5.50 ng/mL. The inter-assay coefficient of variation
was 11.9%. Urinary uromodulin levels were corrected for urine
creatinine before analysis.
Figure 4. Forest Plots of association with rs13333226 and hypertension (adjustment for population stratification was applied using
principal components as appropriate for each cohort). A: Forest plot of association analysis unadjusted for any covariates 221,466 cases and
18,240 controls. B: Forest plot of association analysis adjusted age, age
2, sex and BMI 221,466 cases and 18,240 controls. C: Forest plot of association
analysis in the cohorts where eGFR was available and adjusted for age, age
2, sex, BMI 27427 controls and 5739 cases. D: Forest plot of association
analysis in the cohorts where eGFR was available and adjusted for age, age
2, sex, BMI and eGFR 27427 controls and 5739 cases.
doi:10.1371/journal.pgen.1001177.g004
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The genomewide association study (GWAS) samples were
genotyped using Illumina 550K Single and Illumina 610 Quad V1
BeadChip (Illumina, Inc., San Diego, CA, USA). We included
551,629 SNPs common to both the Single and Quad chips, for
analysis. SNPs with a minor allele frequency (MAF) ,1% or in
significant Hardy-Weinberg disequilibrium (P,1610
27) in pooled
samples were removed leaving 521,220 SNPs for analysis. We
assessed population structure within the data using principal
components analysis as implemented in EIGENSTRAT [37] to
infer continuous axes of genetic variation. After data quality
control for unspecified sex (5 subjects removed), relatedness/
duplicates (68 individuals removed), multidimensional scaling plot
outliers (33 individuals removed), genetic outliers - which are
defined as individuals whose ancestry is at least 6 s.d. from the
mean on one of the top ten axes of variation on principal
component analysis (388 individuals removed) and genotyping
success of ,95% (92 individuals removed), genotype information
from 1,621 cases and 1,699 controls (1,510 males and 1,810
females) was available for analysis. Untyped SNPs were imputed
using IMPUTE v1 [38] with data from the August 2009 release of
CEU phased haplotypes from Pilot 1 of the 1000 Genomes Project
NCBI Build 36 (dbSNP b126) as the reference panel (from https://
mathgen.stats.ox.ac.uk/impute/impute_v1.html). The probability
threshold used for calling an imputed genotype was 0.9. Association
analysis was performed using SNPTEST [38] taking into account
uncertainty in imputation.
Statistical analysis
In the GWAS samples, we tested each SNP for association using
an additive genetic model and logistic regression with adjustment
for significant ancestry principal components [37] to correct for
population stratification. There was still a slight overall inflation of
test statistics, with a genomic control inflation factor (l) of 1.07
(Figure 2). All results are presented after application of genomic
control to correct for this residual inflation [39]. Additionally two
logistic regression analyses were performed, with adjustment for
age, age
2, sex and BMI and with adjustment for age, age
2, sex,
BMI and eGFR. Multiple linear regression was used to test
association between genotype and urinary uromodulin levels,
Table 5. Univariate association analysis of rs13333226 in 110
participants from the HERCULES Study.
AA (n=52) AG (n=46) GG (n=12) p-value
Male:Female (n) 28/24 18/28 7/5 0.258
Age (years) 58 (49–67) 56 (49–66) 59 (49–66) 0.889
Body mass
index (Kg/m
2)
26.1
(23.6–29.3)
24.4
(21.8–29)
24.7
(24–28)
0.175
Body surface
area (m
2)
1.84
(1.72–1.98)
1.76
(1.62–1.92)
1.87
(1.77 – 2.00)
0.045
24 h SBP
(mm Hg)
115.4
(107.7–123.0)
113.2
(105.9–124.8)
118.4
(111.4–130.7)
0.555
24 h DBP
(mm Hg)
76.3
(69.8–81.1)
77.1
(71.5–85.2)
77.7
(71.1–87.7)
0.547
Hypertension* (%) 33 30 25 0.846
Fasting plasma
Sodium (mmol/L) 139.7
(138.1–141.8)
139.9
(138.2–141.5)
140.3
(138.4–142.7)
0.708
Potassium (mmol/L) 4.0 (3.8–4.3) 4.0 (3.7–4.1) 3.8 (3.6 – 4.0) 0.041
Urea (mmol/L) 5.3 (4.4–6.1) 4.8 (4.4–6) 4.4 (4.1 – 5.0) 0.141
Creatinine
(mmol/L)
82
(73.5 – 91.5)
81
(73–88)
76.5
(72.5–80.5)
0.225
Urate
(mmol/L)
318
(290–378)
321
(262–373)
294
(268–318)
0.163
24 h urine
Uromodulin
(mg/L)
30.8
(15.6–51.7)
24.5
(14.2–42.5)
14
(10.6–16.5)
0.005
Uromodulin
(mg/24 h)
53 (25–76) 40 (28–68) 17 (14–33) 0.005
Urine volume
(mL)
1725
(1200–2375)
1665
(1150–2100)
1773
(1125–2300)
0.864
Creatinine clearance
(mL/min)
98.9
(70.5–123)
93.7
(75.4–123.3)
109.4
(86.2–125.1)
0.607
Creatinine excretion
(mmol/kg/24 h)
0.15
(0.12–0.19)
0.16
(0.13–0.19)
0.16
(0.12–0.19)
0.745
Urine Sodium
(mmol/24 h)
138 (86–176) 134 (92–175) 109 (84–161) 0.785
Urine Potassium
(mmol/24 h)
59 (37–84) 61 (45–74) 48 (39–80) 0.865
Fractional Excretion
Sodium (%)
1.2 (0.6–1.8) 1.2 (0.8–1.7) 0.7 (0.6–1.7) 0.696
Fractional Excretion
of Lithium (%)
0.10
(0.07–0.17)
0.15
(0.09–0.21)
0.11
(0.06–0.15)
0.031
Data are median (interquartile range).
*Hypertension defined based on 24 hour ambulatory blood pressure (.135/85
or on antihypertensive treatment).
doi:10.1371/journal.pgen.1001177.t005
Table 4. Univariate association analysis of rs13333226 in 256
hypertensive patients from the BRIGHT study.
AA
(n=141)
AG
(n=93)
GG
(n=22) p-value
Male:Female 0.7 0.8 0.6 0.763
Age (years) 64.7(8.4) 63.9(7.8) 59.5(9.5) 0.036
Body mass
index (Kg/m
2)
26.8(4.6) 26.8(5.4) 27.2(3.9) 0.927
Body surface
area (m
2)
1.8 (0.2) 1.9 (0.2) 1.8 (0.2) 0.494
SBP (mm Hg) 156(19.5) 151.5(18.9) 153.3(14.5) 0.205
DBP (mm Hg) 93.1(10) 90.9(10.7) 93.3(10.3) 0.266
Sodium (mmol/L 138.6(3.1) 138.9(3) 137.8(2.9) 0.341
Potassium (mmol/L) 4.4(0.9) 4.2(0.8) 4.4(1) 0.429
Urea (mmol/L) 6.3(1.6) 5.7(1.6) 6(1.6) 0.025
Creatinine (mmol/L) 92.2(21.7) 88.4(18.7) 82.9(20) 0.096
Urate (mmol/L) 0.3 (0.1) 0.3 (0.1) 0.3 (0.1) 0.726
eGFR (ml/min/
1,73 m
2)
67.6(16.2) 70.3(12.3) 79.5(15.2) 0.005
Creatinine
Clearance (ml/min)
70.6 (20.3) 76.2 (20) 86.6 (26.6) 0.004
Urine Sodium
(mmol/24 h)
139.1(61.9) 158.9(70.6) 142.4(58.3) 0.073
Urine Potassium
(mmol/24 h)
66.4(24.1) 78.8(54) 69.2(18.8) 0.050
Creatinine excretion
(mmol/24 h)
10.2(3.6) 10.8(4.6) 10.7(3.1) 0.520
Uromodulin (mg/L) 5.3(5.3) 5.2(5.5) 3.2(3.4) 0.234
Fractional Excretion
Sodium (%)
0.92 (0.37) 0.95 (0.36) 0.73 (0.19) 0.032
doi:10.1371/journal.pgen.1001177.t004
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relevant covariates. In the GRECO study, as the numbers of GG
genotypes were small, AG and GG were combined for analysis.
Non-normally distributed traits were tested using the non-
parametric Kruskal Wallis test.
Validation analysis
In validation samples, SNPs were tested for association using
logistic regression, with adjustment for ancestry principal compo-
nents where available to correct for population stratification.
Meta-analysis of the combined discovery and validation results was
conducted using an inverse-variance weighted (fixed-effects) meta-
analysis.
In the meta-analysis, a genomewide significance threshold of
5610
–8 corresponding to a P value of 0.05 with a Bonferroni
correction for 1 million independent tests was considered a priori as
genomewide significant [40].
Continuous BP trait modeling
The associations between the validated SNP and SBP and DBP
were analysed separately in the Stage 1 samples of the Global
BPgen consortium (n=34,433) and in the overall MDC
(n=27,000) and MPP (n=17,700) cohorts [9,26,29]. The results
were combined using fixed-effect inverse variance weighted meta-
analysis. Continuous SBP and DBP were adjusted for age, age
2,
body mass index and any study-specific geographic covariates in
sex-specific linear regression models. In individuals taking
antihypertensive therapies, blood pressure was imputed by adding
15 mm Hg and 10 mm Hg for SBP and DBP, respectively [9,41].
Survival analysis
We performed multivariable Cox proportional hazards models
to examine the association between biomarkers and incident
events. (myocardial infarction, stroke, coronary death). Two
models, one adjusted for age, sex, BMI , SBP and smoking status
and another adjusting for age, sex, BMI , SBP, DBP and smoking
status were analysed. We confirmed that the proportionality of
hazards assumption was met. The results are presented as hazard
ratios and 95% confidence intervals per copy of the G allele.
Survival analysis was performed using SPSS version 13.0 for
Windows (SPSS Inc).
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Table 6. Univariate association analysis of urinary uromodulin
in relation to rs13333226 polymorphism and response to high
and low sodium intake (GRECO Study).
AA (n=40)
AG and GG
(n=24) p-value
Male:Female (n) 40/0 24/0 1.0
Age (years) 26 (8) 23 (6) 0.105
Body mass index (Kg/m
2) 23.4 (2.7) 23.4 (2.1) 1.0
Body surface area (m
2) 2.05 (0.14) 2.03 (0.15) 0.590
SBP LS (mm Hg) 120 (10) 121 (10) 0.670
DBP LS (mm Hg) 68 (9) 70 (6) 0.453
SBP HS (mm Hg) 123 (10) 124 (10) 0.805
DPB HS (mm Hg) 69 (8) 70 (7) 0.661
GFR LS (mL/min/1.73 m
2) 109 (13) 103 (14) 0.127
GFR HS (mL/min/1.73 m
2) 114 (14) 116 (15) 0.719
ERPF LS (mL/min/1.73 m
2) 472 (74) 449 (68) 0.209
ERPF HS (mL/min/1.73 m
2) 502 (90) 489 (68) 0.529
ECV LS (L/1.73 m
2) 16.5 (1.9) 16.3 (1.6) 0.657
ECV HS (L/1.73 m
2) 17.2 (1.7) 18.0 (1.9) 0.093
Fractional Excretion Sodium LS
(%)
0.19 (0.18) 0.22 (0.25) 0.342
Fractional Excretion Sodium HS
(%)
0.99 (0.35) 0.82 (0.31) 0.001
Plasma Renin Activity LS
(nmol/L/h)
6.3 (3.7) 6.6 (3.1) 0.723
Plasma Renin Activity HS
(nmol/L/h)
2.5 (1.5) 2.0 (0.9) 0.155
Uromodulin LS median (IQR)
(mg/L)
10.3 (6.9–15.6) 9.0 (6.3–14.2) 0.002
Uromodulin HS median (IQR)
(mg/L)
11.9 (7.5–27.9) 12.2 (7.2–21.3) 0.513
LS: Low sodium diet, HS: High sodium diet; Data are presented as mean (SD). P-
value comparing AA versus AG+GG.
doi:10.1371/journal.pgen.1001177.t006
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